Hyperpigmentation Disorder Treatment Market is expected to reach US$ 11.78 billion by 2030

Cosmeceutical Segment to Hold Significant Share of Hyperpigmentation Disorder Treatment Market During 2022–2030

According to our latest study on "Hyperpigmentation Disorder Treatment Market Forecast to 2030 – Global Analysis – Treatment Type, Condition, and End User," the market value is expected to reach US$ 11.78 billion by 2030 from US$ 6.68 billion in 2022; the market is estimated to record a CAGR of 7.4% during 2022–2030. The report emphasizes the key factors driving the market and prominent players' developments. Factors such as a rise in the prevalence of melasma and the increasing number of hyperpigmentation disorder awareness programs propel the market growth. However, the high cost of treatments impedes the growth of the market. Further, the growing adoption of novel products based on path-3 technology is expected to bring new hyperpigmentation disorder treatment market trends in the coming years.

Melasma, one of the most dominant hyperpigmentation conditions, is characterized by symmetrical light to dark muddy-brown macules with borders on the face, particularly the chin, upper lip, nose, forehead, and cheeks. It is prevalent among women and those with darker complexion. Malar, mandibular, and centrofacial clinical features are common in melasma. Sun exposure, hormonal variations, pregnancy, hereditary factors, cosmetics, and medicines have all been linked to the development of melasma. According to a study published in Elsevier BV in September 2023, various studies have estimated that the overall prevalence of melasma in the general population ranges from 1% to 50%. Furthermore, 55–64% of people diagnosed with melasma have reported a family history of the same condition. Moreover, a greater prevalence is reported in individuals of East Asian and Hispanic origins as well as in patients with high Fitzpatrick skin phototypes (IV to VI); it is also higher in individuals living in locations that receive intense UV radiation.

Hyperpigmentation Disorder Treatment Market, by Region, 2022 (%)

Source: The Insight Partners Analysis

Pregnancy is another common cause of melasma. This condition also impacts women taking oral contraceptives and hormones. Estrogen, progesterone, and melanocyte-stimulating hormone levels normally rise during the third trimester of pregnancy, which may act as a risk factor. According to a study published in the National Center for Biotechnology Information (NCBI) in August 2023, melasma is more common in reproductive years, and it rarely occurs before puberty; the condition occurs in 15–50% of pregnant women, and its prevalence ranges from 1.5% to 33%, depending on the population in a different region. Therefore, an upsurge in melasma prevalence triggers the demand for hyperpigmentation treatments. Thus, the surging cases of melasma in the global population drive the hyperpigmentation disorder treatment market growth.

The hyperpigmentation disorder treatment market analysis has been carried out by considering the following segments: treatment type, condition, and end user. By treatment type, the market is segmented into cosmeceutical, light or laser therapy, microdermabrasion, chemical peels, cryotherapy, and others. The cosmeceutical segment held the largest hyperpigmentation disorder treatment market share in 2022. Further, the microdermabrasion segment is anticipated to register the highest CAGR during the forecast period. 

The market, by condition, is categorized into melasma, solar lentigines, post-inflammatory hyperpigmentation, and others. The melasma segment held the largest hyperpigmentation disorder treatment market share in 2022. It is further anticipated to register the highest CAGR during the forecast period. The market, by end user, is categorized into hospitals, dermatology centers, and others. The hospitals segment held the largest market share in 2022, Further, the dermatology centers segment is anticipated to register the highest CAGR during the forecast period.

Hyperpigmentation Disorder Treatment Market, by Region:

The geographic scope of the hyperpigmentation disorder treatment market report entails North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). In 2022, North America held the largest share of the market. The increasing numbers of clinics and hospitals providing hyperpigmentation disorder treatment services, and the evolving demographics of the US with the growth of the Hispanic population with a dark skin type is driving the growth of the market. Further, the increasing number of product launches and approvals, the surging number of aesthetic clinics, and growing access to numerous hyperpigmentation treatments are among the factors propelling the hyperpigmentation disorder treatment market growth in Canada. For instance, in June 2023, Sun Pharma Canada Inc. received Health Canada's approval of PRABSORICA LD (isotretinoin capsules). ABSORICA LD is a new and only micronized formulation of isotretinoin, which is the first formulation developed in over a decade to treat severe acne in patients aged 12 and older.

Asia Pacific is expected to record the highest CAGR in the hyperpigmentation disorder treatment market during the forecast period. China holds a significant share of the market in this region. The burgeoning aesthetic industry, high prevalence of melasma, and growing awareness of cosmetic procedures and minimally invasive procedures (chemical peel, cryotherapy, light or laser therapy) propel the market growth in this country. Additionally, there is an increasing preference for younger-looking skin in older adults in Japan. Thus, they value holistic approaches to skincare. Japan records the highest per capita expenditure in Asia Pacific, which, in turn, contributes to the hyperpigmentation disorder treatment market in the country.

Apart from factors driving the market, the hyperpigmentation disorder treatment market report emphasizes key developments by prominent players. AbbVie Inc, Bayer AG, Epipharm AG, Galderma Laboratories, Obagi Cosmeceuticals LLC, Lutronic Corporation, La Pristine, L’oreal S.A, Pierre Fabre Group, and Vivier Pharma USA are among the prominent players contributing to the hyperpigmentation disorder treatment market size. These companies have been implementing various strategies that contribute to their growth and lead to various changes in the market. Organic strategies implemented by them include product launches, expansions, and product approvals, while inorganic strategies include collaborations and partnerships.

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com